[{"id":"ef3ee7ea-e266-49a7-bd2d-0c9eccee4dcb","acronym":"EvoPAR-PR02","url":"https://clinicaltrials.gov/study/NCT06952803","created_at":"2025-06-07T14:51:41.431Z","updated_at":"2025-06-07T14:51:41.431Z","phase":"Phase 3","brief_title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","source_id_and_acronym":"NCT06952803 - EvoPAR-PR02","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • saruparib (AZD5305)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 05/30/2025","start_date":" 05/30/2025","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 04/30/2036","study_completion_date":" 04/30/2036","last_update_posted":"2025-05-30"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"1eeb0f08-7927-4438-a063-9e9859dc3e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516289","created_at":"2025-02-26T10:01:45.127Z","updated_at":"2025-02-26T10:01:45.127Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","source_id_and_acronym":"NCT06516289","lead_sponsor":"Fudan University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"57e9cf07-fbd3-4b60-b000-b857b664ab20","acronym":"ATARI","url":"https://clinicaltrials.gov/study/NCT04065269","created_at":"2021-01-18T19:55:05.811Z","updated_at":"2025-02-25T15:08:44.072Z","phase":"Phase 2","brief_title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","source_id_and_acronym":"NCT04065269 - ATARI","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-07-11"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"},{"id":"79ef0e88-111d-46b4-b454-13193bb2c7c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05002868","created_at":"2021-08-12T13:54:30.231Z","updated_at":"2024-07-02T16:35:05.010Z","phase":"Phase 1","brief_title":"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors","source_id_and_acronym":"NCT05002868","lead_sponsor":"Rhizen Pharmaceuticals SA","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RP12146"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 04/25/2024","primary_completion_date":" 04/25/2024","study_txt":" Completion: 04/25/2024","study_completion_date":" 04/25/2024","last_update_posted":"2024-05-08"},{"id":"7d4bee37-66f9-444a-b255-8785fecda7ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04182516","created_at":"2021-01-18T20:23:35.888Z","updated_at":"2024-07-02T16:35:08.443Z","phase":"Phase 1","brief_title":"Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT04182516","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itareparib (NMS-293)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/25/2019","start_date":" 11/25/2019","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-22"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"f6337414-9975-408c-9a77-c574d3607574","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078670","created_at":"2023-10-12T22:13:53.034Z","updated_at":"2024-07-02T16:35:33.749Z","phase":"Phase 1/2","brief_title":"PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078670","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" PD-L1 • BRCA1 • BRCA2 • CHEK2","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-10-12"},{"id":"af433384-87c1-4543-9d9d-fa60f08304f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05740956","created_at":"2023-02-23T15:01:09.263Z","updated_at":"2024-07-02T16:35:33.868Z","phase":"Phase 1","brief_title":"A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05740956","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" HRD • MUC16","pipe":" | ","alterations":" HRD","tags":["HRD • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10502"],"overall_status":"Recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-11"},{"id":"d985b472-e638-4ad1-93ec-e5ff886eaca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05473624","created_at":"2022-07-26T17:09:56.344Z","updated_at":"2024-07-02T16:35:35.416Z","phase":"Phase 1","brief_title":"Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05473624","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-28"},{"id":"22a22b29-ff5a-48ed-af0f-f0ab690533a4","acronym":"SOLTI NEOPARP","url":"https://clinicaltrials.gov/study/NCT01204125","created_at":"2021-01-18T04:49:29.973Z","updated_at":"2024-07-02T16:37:24.185Z","phase":"Phase 2","brief_title":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT01204125 - SOLTI NEOPARP","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • iniparib (BSI 201)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2017-03-22"}]